CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
11C-acetate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01917136
NCT01917136Phase 2Completed
CompareCT.gov

Evaluation of Regional Myocardial Perfusion, Glucose Utilization and Oxidative Metabolism in Patients With Pulmonary Hypertension Using Combined [11C]Acetate and [18F]Fluorodeoxyglucose (FDG) PET/CT and Cardiovascular MRI

University of Pennsylvania·interventional·Posted Aug 6, 2013·Updated Feb 5, 2019

In Brief

A Phase 2 clinical trial evaluating 11C-acetate, [18F]Fluoro-2-deoxy-2-D-glucose, and 1 other intervention for Pulmonary Hypertension. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This study is looking at differences in metabolism and functional imaging between pulmonary hypertension subjects with normal right ventricular function and persistent right ventricular dysfunction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, University of Maryland, Yale University, Washington University School of Medicine, The Cardiovascular Medical Research and Education Fund

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 6, 2013
Enrollment StartAug 1, 2013
Primary CompletionOct 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 12.9 years ago

Interventions

11C-acetatedrug

For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate

[18F]Fluoro-2-deoxy-2-D-glucosedrug

For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG

Cardiac MRIother

Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.